Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that it has completed a non-brokered private placement, raising approximately $666,400 through the issuance of 2,221,334 units at $0.30 per unit.
Each unit includes one common share and a warrant, allowing the purchase of an additional share at $0.45 within five years.
The proceeds of the private placement will support the company’s ongoing Phase 2 Non-Muscle Invasive Bladder Cancer clinical study, preclinical research on Rutherrin, and general corporate needs.
Theralase is a clinical-stage pharmaceutical company focused on developing light, radiation, sound, and drug-activated compounds and systems to safely and effectively target cancers, bacteria, and viruses.